1. Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial. Issue 12 (December 2020) Authors: Rocconi, Rodney P; Grosen, Elizabeth A; Ghamande, Sharad A; Chan, John K; Barve, Minal A; Oh, Jonathan; Tewari, Devansu; Morris, Peter C; Stevens, Erin E; Bottsford-Miller, Justin N; Tang, Min; Aaron, Phylicia; Stanbery, Laura; Horvath, Staci; Wallraven, Gladice; Bognar, Ernest; Manning, Luisa; N... Journal: Lancet oncology Issue: Volume 21:Issue 12(2020) Page Start: 1661 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗